期刊
PHARMACOLOGY RESEARCH & PERSPECTIVES
卷 9, 期 2, 页码 -出版社
JOHN WILEY & SONS LTD
DOI: 10.1002/prp2.757
关键词
-
Monoclonal antibodies (Mabs) are key drugs in cancer treatment, serving as targeted therapies or immune checkpoint inhibitors (ICIs). However, the individual dosing and therapeutic drug monitoring for these drugs need to take into account their unique pharmacological characteristics.
Monoclonal antibodies (Mabs) have become key drugs in cancer treatment, either as targeted therapies or more recently as immune checkpoint inhibitors (ICIs). The fact that only some patients benefit from these drugs poses the usual question in the field of onco-hematology: that of the benefit of individual dosing and the potential of therapeutic drug monitoring (TDM) to carry out this individualization. However, Mabs present unique pharmacological characteristics for TDM, and the pharmacokinetic-pharmacodynamic relationship observed should be interpreted differently than that observed for conventional drugs and small molecules. This pharmacology practice review has been summarized from a public debate between the authors at the International TDM and Clinical Toxicology meeting in Banff, 2020, regarding the potential roles of TDM in the Mab/ICI setting.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据